[Thymalin in the combined treatment of parkinsonism patients].
Overall, fifteen patients with stage IB-2A (stages 1.5 to 2.5 as per UPDRS scale) idiopathic parkinsonism who ranged from 45 to 72 years old were examined before and after the course of treatment with thymalin. A positive time-related course was noted of the patients' general physical/mental well-being, parkinsonian triad of symptoms (tremor, rigidity, hypokinesia) associated with objective parameters characterizing the state of cerebral integrative functions (by the method of determining the biological age of the central nervous system). Efficacy of thymolin use is confirmed by EEG mapping; there has been established a significant decrement in the power of alpha rhythm in the anterocentral regions of the brain, which fact suggests to us an improvement in the cortical neurodynamics.
Musienko
G V
GV
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004569:Electroencephalography / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D013951:Thymus Hormones / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D000978:Antiparkinson Agents; D013951:Thymus Hormones; C032805:thymalin
Timalin v kompleksnom lechenii bol'nykh parkinsonizmom.